Navigation Links
MIGENIX releases CEO message #22
Date:2/15/2008

VANCOUVER and San Diego, CA, Feb. 15 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, has issued its 22nd CEO Message from Jim DeMesa, MD, President & CEO. Today's CEO Message provides a discussion of the company's expected progress in 2008 and into 2009, including:

Omigard (prevention of catheter-related infections):

- Phase III results in H2/08

- NDA submission in H1/09

- Rest of world partnership

Celgosivir (hepatitis C virus):

- Phase II viral kinetics study results (including 600mg) in Q3/08

- Partnership

CLS001 (rosacea and other dermatologic conditions):

- Enter Phase III clinical development

MX-2401 (serious bacterial infections):

- Further advancement through preclinical development (clinicals

could begin in 2009)

To obtain a copy of the complete CEO Message, please visit the MIGENIX web site at http://www.migenix.com or contact Investor Relations at 1-800-665-1968, Extension 233 (also available on SEDAR and EDGAR).

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II and preclinical), the prevention of catheter-related infections (Phase III) and the treatment of dermatological diseases (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix.com.

"Jim DeMesa"

James M. DeMesa, M.D.

President & CEO

FORWARD-LOOKING STATEMENTS

This news rel
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
2. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
3. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
6. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
7. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
8. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
9. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
10. Intrasphere Technologies Releases PharmaCM Submissions Management and Authoring Module Powered by Microsoft Office SharePoint Server 2007
11. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... Ohio (PRWEB) July 10, 2014 Understanding ... ion channel-expressing cell lines, and the gap that currently ... cells that expand its industry-leading portfolio of validated ion ... on ion channel-expressing cell lines, as ion channels control ... to control this activity creates the potential to treat ...
(Date:7/10/2014)... Angeles, CA (PRWEB) July 10, 2014 ... and Bioanalytical techniques during 18-20 August, 2014 at Double ... critically review the recent developments in Analytical & Bioanalytical ... the globe. , Speaking on this occasion, Dr. Srinubabu ... Analytica Acta conference is a remarkable one in ...
(Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... on December 10, 2007, SPACE COAST, Fla., ... its Third Annual Colloquium on the Law of,Transbeman ... will,be held December 10, 2007 along Florida,s Space ... flesh and computerized,substrate., The colloquia are open ...
... quarters of our universe is made up of some weird, ... dark energy. This month in Physics World, Eric ... at Berkeley, reveal how little we know about dark energy ... we can expect in the coming decade from a series ...
... Inc. (Nasdaq: SGMO ) announced today that Edward ... the progress of,Sangamo,s ZFP Therapeutic development programs and an ... on Tuesday, December 4, 2007 at,the BMO Capital Markets ... The presentation will be webcast live and may be ...
Cached Biology Technology:International Human Rights Day Recognized by Terasem Movement, Inc.'s Third Annual Colloquium on the Law of Transbeman Persons 2Dark energy -- 10 years on 2Sangamo BioSciences to Present at the BMO Capital Markets Health Care Conference 2
(Date:7/10/2014)... 2014 It is a great honor for ... of the world-renowned Thoracic and Cardiovascular surgeon, Mark E ... Dr. Ginsburg, with over 34 years of experience, is ... Good Samaritan Regional Medical Center. Dr. Ginsburg has been ... and is considered an expert in the implantation of ...
(Date:7/10/2014)... DALLAS , July 3, 2014 ... Sensors Market by Type (Swipe And Area), Material (Optical ... Defense, Healthcare, Commercial Security and Banking & Finance), and ... 2020", published by MarketsandMarkets, the global Fingerprint Sensors Market ... at a high CAGR of 16.8% from 2014 to ...
(Date:7/10/2014)... Sweden , July 7, 2014 ... its first major design win (DW). A Chinese Top 5 ... the planned start of mass production in October 2014.   ... a Chinese Top 5 smartphone OEM, which has a planned ... and a target sales volume for this phone of 3 ...
Breaking Biology News(10 mins):Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
... In our not-so-distant evolutionary past, stress often meant ... so part of our body,s stress response is ... Medicine Partnership Unit (MMPU), a collaboration between the ... and the University of Heidelberg Medical Centre, have ...
... in the long-standing arms race between the flowering plant ... Duke University researchers have found that the little mustard ... prepare for the greatest onslaught of infectious spores released by ... time of day it is and change their activities accordingly, ...
... PORTLAND, Ore. -- The pediatric cardiac team at Oregon ... first in the region and one of a handful ... without open-heart surgery. To date, four patients have ... Adult Congenital Cardiac Catheterization Lab. All reported immediate improvement ...
Cached Biology News:Blood-clotting protein linked to cancer and septicemia 2Blood-clotting protein linked to cancer and septicemia 3Plant's immune defense revs up for the morning attack 2Plant's immune defense revs up for the morning attack 3OHSU fixes complex heart problems without open-heart surgery 2
...
...
...
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
Biology Products: